Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

@article{As2020DifferentID,
  title={Different infusion durations for preventing platinum-induced hearing loss in children with cancer.},
  author={Jorrit W van As and H. van den Berg and E. C. van Dalen},
  journal={The Cochrane database of systematic reviews},
  year={2020},
  volume={1},
  pages={
          CD010885
        }
}
  • Jorrit W van As, H. van den Berg, E. C. van Dalen
  • Published 2020
  • Medicine
  • The Cochrane database of systematic reviews
  • BACKGROUND Platinum-based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different platinum infusion durations have been studied. This review is the third update of a previously published Cochrane Review. OBJECTIVES To assess the effects of different… CONTINUE READING